9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patients with acute coronary syndromes have elevated plasma levels of the proinflammatory, prothrombotic cytokine CD40 ligand (sCD40L). Statins inhibit CD40L signaling in vitro, but there are no prospective studies of statins and sCD40L in acute coronary syndromes.

          Related collections

          Author and article information

          Journal
          Circulation
          Circulation
          Ovid Technologies (Wolters Kluwer Health)
          1524-4539
          0009-7322
          Jul 27 2004
          : 110
          : 4
          Affiliations
          [1 ] Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass 02115, USA.
          Article
          01.CIR.0000136588.62638.5E
          10.1161/01.CIR.0000136588.62638.5E
          15262833
          3f849aeb-9dd2-4fde-8a16-08d4a43a9e27
          History

          Comments

          Comment on this article